Abstract
Sensitivity to glucocorticoid (GC)-evoked apoptosis in lymphoid cell lines correlates closely with GC-mediated suppression of c-Myc expression. To establish a functional role for c-Myc in GC-mediated apoptosis, we have stably expressed MycERTM, the human c-Myc protein fused to the modified ligand-binding domain of the murine estrogen receptor α, in GC-sensitive CEM-C7-14 cells. In CEM-C7-14 cells, MycERTM constitutively imparts c-Myc functions. Cells expressing MycERTM (C7-MycERTM) exhibited a marked reduction in cell death after 72 h in 100 nM dexamethasone (Dex), with 10–20-fold more viable cells when compared to the parental CEM-C7-14 clone. General GC responsiveness was not compromised, as evidenced by Dex-mediated suppression of endogenous c-Myc and cyclin D3, and induction of c-Jun and the glucocorticoid receptor. MycERTM also blunted Dex-mediated upregulation of p27kipI and suppression of the Myc target p53. In comparison to parental CEM-C7-14 cells, Dex-evoked DNA strand breaks were negligible and caspase activation was delayed, but the extent of G1 cell cycle arrest was similar in C7-MycERTM cells. Myc-ERTM did not result in permanent, complete resistance to GC however, and the GC-treated cells eventually died, indicative of redundant or interactive mechanisms in the GC-evoked lytic response of lymphoid cells. Our results emphasize the importance of c-Myc suppression in GC-evoked apoptosis of CEM-C7-14 cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- GCs:
-
glucocorticoids
- GR:
-
GC receptor
- cdks:
-
cyclin dependent kinases
- Dex:
-
dexamethasone
- ER:
-
estrogen receptor
- ERTM:
-
G525R mutant of ER α
- LBD:
-
ligand binding domain
- 4HT:
-
4 hydroxy tamoxifen
- TUNEL:
-
terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-X-nick end labeling
- PARP:
-
poly ADP ribose polymerase
- FBS:
-
fetal bovine serum
- PBS:
-
phosphate buffered saline
- AEBSF:
-
4-[2-aminoethyl]benzensulfonyl fluoride
- ECL:
-
enhanced chemiluminescence
- AFC:
-
7-amido-4-trifluoromethylcoumarin
References
Afrakhte M, Heldin NE, Westermark B . 1998 Cell Growth Diff. 9: 983–988
Askew DS, Ashmun RA, Simmons BC, Cleveland JL . 1991 Oncogene 6: 1915–1922
Bishop JM . 1983 Annu. Rev. Biochem. 52: 301–354
Blackwood EM, Eisenman RN . 1991 Science 251: 1211–1217
Blyth K, Stewart M, Bell M, James C, Evan G, Neil JC, Cameron ER . 2000 Oncogene 19: 773–782
Brunet CL, Gunby RH, Benson RS, Hickman JA, Watson AJ, Brady G . 1998 Cell Death Diff. 5: 107–115
Bruno S, Ardelt B, Skierski JS, Traganos F, Darzynkiewicz Z . 1992 Cancer Res. 52: 470–473
Casteels KM, Gysemans CA, Waer M, Bouillon R, Laureys JM, Depovere J, Mathieu C . 1998 Diabetes 47: 1033–1037
Cheng J, Haas M . 1990 Mol. Cell. Biol. 10: 5502–5509
Chiarugi V, Magnelli L, Cinelli M, Basi G . 1994 Cell. Mol. Biol. Res. 40: 603–612
Dowd DR, MacDonald PN, Komm BS, Haussler MR, Miesfeld R . 1991 J. Biol. Chem. 266: 18423–18426
Eastman-Reks SB, Vedeckis WV . 1986 Cancer Res. 46: 2457–2462
Evan GI, Lewis GK, Ramsay G, Bishop JM . 1985 Mol. Cell. Biol. 5: 3610–3616
Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, Hancock DC . 1992 Cell 69: 119–128
Facchini LM, Penn LZ . 1998 FASEB J. 12: 633–651
Foley GE, Lazarus H, Farber S, Uzman BG, Boone BA, McCarthy RE . 1965 Cancer 18: 522–529
Galaktionov K, Chen X, Beach D . 1996 Nature 382: 511–517
Gaynon PS, Carrel AL . 1999 Adv. Exper. Med. Biol. 457: 593–605
Harmon JM, Norman MR, Fowlkes BJ, Thompson EB . 1979 J. Cell. Physiol. 98: 267–278
Helmberg A, Auphan N, Caelles C, Karin M . 1995 EMBO J. 14: 452–460
Homo-Delarche F . 1984 Cancer Res. 44: 431–437
Jones RM, Branda J, Johnston KA, Polymenis M, Gadd M, Rustgi A, Callanan L, Schmidt EV . 1996 Mol. Cell. Biol. 16: 4754–4764
Kiguchi K, Glesne D, Chubb CH, Fujiki H, Huberman E . 1994 Cell Growth Diff. 5: 995–1004
Laemmli UK . 1970 Nature 227: 680–685
Leung K, Munck A . 1975 Endocrinology 97: 744–748
Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI . 1995 Nucleic Acids Res. 23: 1686–1690
Loffler M, Ausserlechner MJ, Tonko M, Hartmann BL, Bernhard D, Geley S, Helmberg A, Kofler R . 1999 Oncogene 18: 4626–4631
Martins TC, Aguas AP . 1998 Immunology 95: 377–382
Medh RD, Saeed MF, Johnson BH, Thompson EB . 1998 Cancer Res. 58: 3684–3693
Medh RD, Thompson EB . 2000 Cell Tissue Res. 301: 101–124
Miltenberger RJ, Sukow KA, Farnham PJ . 1995 Mol. Cell. Biol. 15: 2527–2535
Montague JW, Cidlowski JA . 1995 Curr. Topics Microbiol. Immun. 200: 51–65
Muller D, Bouchard C, Rudolph B, Steiner P, Stuckmann I, Saffrich R, Ansorge W, Huttner W, Eilers M . 1997 Oncogene 15: 2561–2576
Perez-Roger I, Solomon DL, Sewing A, Land H . 1997 Oncogene 14: 2373–2381
Peukert K, Staller P, Schneider A, Carmichael G, Hanel F, Eilers M . 1997 EMBO J. 16: 5672–5686
Philipp A, Schneider A, Vasrik I, Finke K, Xiong Y, Beach D, Alitalo K, Eilers M . 1994 Mol. Cell. Biol. 14: 4032–4043
Picard D, Salser SJ, Yamamoto KR . 1988 Cell 54: 1073–1080
Rabbitts PH, Watson JV, Lamond A, Forster A, Stinson MA, Evan G, Fischer W, Atherton E, Sheppard R, Rabbitts TH . 1985 EMBO J. 4: 2009–2015
Reisman D, Elkind NB, Roy B, Beamon J, Rotter V . 1993 Cell Growth Diff. 4: 57–65
Reisman D, Thompson EA . 1995 Mol. Endocrinol. 9: 1500–1509
Rhee K, Bresnahan W, Hirai A, Hirai M, Thompson EA . 1995 Cancer Res. 55: 4188–4195
Rosse T, Olivier R, Monney L, Rager M, Conus S, Fellay I, Jansen B, Borner C . 1998 Nature 391: 496–499
Sakamuro D, Prendergast GC . 1999 Oncogene 18: 2942–2954
Sarin A, Wu ML, Henkart PA . 1996 J. Exp. Med. 184: 2445–2450
Shi Y, Glynn JM, Guilbert LJ, Cotter TG, Bissonnette RP, Green DR . 1992 Science 257: 212–214
Spencer CA, Groudine M . 1991 Adv. Cancer Res. 56: 1–48
Srinivasan G, Patel NT, Thompson EB . 1994 Mol. Endocrinol. 8: 189–196
Thompson EB . 1998 Annu. Rev. Physiol. 60: 575–600
Thompson EB . 1999 Trends in Endocrinol. Metab. 10: 353–358
Thompson EB, Thulasi R, Saeed MF, Johnson BH . 1995 Ann. N. Y. Acad. Sci. 761: 261–275
Thulasi R, Harbour DV, Thompson EB . 1993 J. Biol. Chem. 268: 18306–18312
Tobias KE, Shor J, Kahana C . 1995 Oncogene 11: 1721–1727
Vaillant F, Blyth K, Terry A, Bell M, Cameron ER, Neil J, Stewart M . 1999 Oncogene 18: 7124–7134
Vlach J, Hennecke S, Alevizopoulos K, Conti D, Amati B . 1996 EMBO J. 15: 6595–6604
Wagner AJ, Small MB, Hay N . 1993 Mol. Cell. Biol. 13: 2432–2440
Wood KM, Thompson Jr EA . 1984 Mol. Cell. Endocrinol. 37: 169–180
Yatouji S, Liautaud-Roger F, Dufer J . 2000 Cell Prolif. 33: 51–62
Yerly-Motta V, Pavy JJ, Herve P . 1999 Biotechnic & Histochemistry 74: 119–128
Yuh YS, Thompson EB . 1989 J. Biol. Chem. 264: 10904–10910
Zhou F, Thompson EB . 1996 Mol. Endocrinol. 10: 306–316
Acknowledgements
We thank Dr T Littlewood for providing us with the construct pBpuroMycERTM, Dr Thomas Wood and the staff of the Recombinant DNA Laboratory of the Sealy Center for Molecular Sciences for help with sequence analysis of MycER cDNA isolated from C7-MycERTM#22 cells, and Mr Mark Griffin for assistance with Flow Cytometric analyses. We also thank Ms Betty Johnson for cloning CEM-C7-14 cells and for her laboratory managerial skills. This work was supported by grants from the John Sealy Endowment Fund for Biomedical Research (to RD Medh), the Elsa U. Pardee Foundation (to RD Medh), and the National Cancer Institute (to EB Thompson, 2RO1 CA41047). This work was done in conjunction with the Walls Medical Research Foundation.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Medh, R., Wang, A., Zhou, F. et al. Constitutive expression of ectopic c-Myc delays glucocorticoid-evoked apoptosis of human leukemic CEM-C7 cells. Oncogene 20, 4629–4639 (2001). https://doi.org/10.1038/sj.onc.1204680
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204680
Keywords
This article is cited by
-
Label propagation defines signaling networks associated with recurrently mutated cancer genes
Scientific Reports (2019)
-
Epigenetic alteration by DNA-demethylating treatment restores apoptotic response to glucocorticoids in dexamethasone-resistant human malignant lymphoid cells
Cancer Cell International (2014)
-
Erg and AP-1 as determinants of glucocorticoid response in acute lymphoblastic leukemia
Oncogene (2013)
-
Elucidating the identity of resistance mechanisms to prednisolone exposure in acute lymphoblastic leukemia cells through transcriptomic analysis: A computational approach
Journal of Clinical Bioinformatics (2011)
-
Evaluation of the NOD/SCID xenograft model for glucocorticoid-regulated gene expression in childhood B-cell precursor acute lymphoblastic leukemia
BMC Genomics (2011)